Esophageal cancer
Conditions
Interventions
Recurrence and metastasis group:MRD-positive
Recurrence/metastasis-free group:MRD-negative
Sponsors
HenanCancerHospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Provision of signed informed consent and age >18 years; 2.Esophageal squamous cell carcinoma confirmed by histology or cytology, without considering any mutation characteristics of the patient; 3.Patients can be diagnosed with esophageal cancer that can be treated with curative surgery; 4.Patients can provide remaining paraffin embedded tumor tissue samples (FFPE) or fresh tissue samples collected from the biological sample center during the same period of diagnosis and treatment, and cooperate with the collection of peripheral blood at various nodes; 5.No other anti-tumor treatments have been performed in the past; 6.Patient PS score 0-2; 7.Provide clinical pathological and imaging data required for the research process in conjunction with the treatment process;
Exclusion criteria
Exclusion criteria: 1.Patients with previous malignant tumors are not eligible to participate in the study unless they have achieved complete remission for at least 5 years prior to enrollment and do not require any other treatment or do not require any other treatment during the study period; 2.The patient has severe anemia; 3.Incomplete subject related information; 4.Pregnant, preparing for pregnancy or breastfeeding women; 5.Individuals with a history of severe mental illness; 6.The patient receives a blood transfusion two weeks before or during the surgical resection; 7.The patient has any other conditions that the researchers believe may interfere with the subject's assessment; 8.Unable to follow up with the study according to the determined clinical follow-up period; 9.Unable to accept or provide designated efficacy evaluation methods such as imaging;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence Rate in MRD+;Recurrence-Free Survival(RFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Consistency between MRD and traditional monitoring methods;MRD Clearance Rate;The interval between the occurrence time of MRD positivity and the recurrence time;Sensitivity and specificity of comprehensive treatment response index in predicting recurrence;MRD in each subgroup predicts the efficacy of recurrence and metastasis;Sensitivity and specificity of MRD in predicting recurrence; | — |
Countries
China
Contacts
Public ContactWei Bing
Henan Cancer Hospital
Outcome results
None listed